Laurus Labs
Laurus Labs Limited, commonly referred to as Laurus Labs, is a prominent player in the pharmaceutical industry, headquartered in Hyderabad, India. Founded in 2005, the company has established itself as a leader in the development and manufacturing of active pharmaceutical ingredients (APIs), generic formulations, and contract research services. With a strong focus on high-quality production, Laurus Labs offers a diverse portfolio that includes antiretroviral, oncology, and cardiovascular products, setting itself apart through its commitment to innovation and regulatory compliance. The company has achieved significant milestones, including multiple approvals from global regulatory authorities, which solidify its market position. Recognised for its robust research and development capabilities, Laurus Labs continues to expand its operational footprint across various regions, contributing to its reputation as a trusted partner in the pharmaceutical sector.
DitchCarbon Score
How does Laurus Labs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laurus Labs's score of 32 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Laurus Labs's reported carbon emissions
In 2025, Laurus Labs reported significant carbon emissions, totalling approximately 315,457,000 kg CO2e for Scope 1 and 181,901,000 kg CO2e for Scope 2, alongside 91,787,000 kg CO2e for Scope 3 emissions. This data reflects their commitment to transparency in emissions reporting, with all three scopes disclosed. The company has set near-term climate targets, although it has not committed to a net-zero goal. As of December 2023, Laurus Labs is classified as "Committed" to near-term targets, indicating a proactive approach to reducing its carbon footprint within the pharmaceuticals, biotechnology, and life sciences sector. In 2024, Laurus Labs' emissions were slightly higher, with Scope 1 at 321,270,000 kg CO2e, Scope 2 at 176,679,000 kg CO2e, and Scope 3 at 87,212,000 kg CO2e. This data illustrates the ongoing challenge of managing emissions in a growing industry. The company has not inherited emissions data from any parent organisation, ensuring that its reported figures are solely reflective of its own operations. Laurus Labs continues to focus on sustainability initiatives, aiming to improve its emissions intensity and overall environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Scope 1 | 61,436,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 205,680,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Laurus Labs is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
